

Q2 2024 *Results*



- We are continuing our strong performance in 2024, with broad-based, double-digit sales growth in the second quarter, and making important progress in our pipeline of new medicines. •

Paul Hudson

Chief Executive Officer, Sanofi

Q2 2024 company sales

€10,745m

+10.2% at constant exchange rates

+7.8% on a reported basis

Q2 2024 business earnings per share

€1.73

+4.0% at constant exchange rates

-0.6% on a reported basis

Robust growth driven by portfolio transformation



Dupixent

€3,303m

+29.2%

at constant
exchange rates



Pharma launches

€689m

+80.4%

at constant
exchange rates



Vaccines

€1,142m

-4.8%

at constant
exchange rates



Other medicines

€4,305m

-2.1%

at constant
exchange rates



Opella

€1,306m

+9.6%

at constant
exchange rates

sanofi

Q2 2024 *Results*

Sales by geography

US
€4,751m

Europe
€2,402m

Rest of the World
€3,592m

Pipeline progress



3 regulatory approvals

4 regulatory submissions

Sustainability



Sanofi named world's
7th most sustainable company
by TIME Magazine

For further information on Q2 2024 results and definitions of financial indicators, please refer to the press release issued on July 25, 2024 at: www.sanofi.com/en/investors